A phase II Study of OSI-774 in unresectable hepatocellular carcinoma.

被引：0
|
作者：
Thomas, MB
Faria, S
Tamm, E
Rashid, A
Charnsangavej, C
Dancey, J
Abbruzzese, J
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6092S / 6092S
页数：1
相关论文
共 50 条
  • [31] Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
    Y Chao
    W-K Chan
    MJ Birkhofer
    OY-P Hu
    S-S Wang
    Y-S Huang
    M Liu
    J Whang-Peng
    K-H Chi
    W-Y Lui
    S-D Lee
    British Journal of Cancer, 1998, 78 : 34 - 39
  • [32] Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma.
    Delman, KA
    Brown, TD
    Thomas, M
    Ensor, CM
    Holtsberg, FW
    Bomalaski, JS
    Clark, MA
    Curley, SA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 342S - 342S
  • [33] Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer.
    Winer, E
    Cobleigh, M
    Dickler, M
    Miller, K
    Fehrenbacher, L
    Jones, C
    Justice, R
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S115 - S115
  • [34] Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma.
    Acoba, Jared David
    Rho, Young
    Fukaya, Erin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 580 - 580
  • [35] N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first- or second-line therapy for metastatic breast cancer (MBC).
    Graham, DL
    Hillman, DW
    Hobday, TJ
    Rousey, SR
    Nair, SG
    Soori, GS
    Sabagh, TM
    Perez, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 39S - 39S
  • [36] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    Hidalgo, M
    Siu, LL
    Nemunaitis, J
    Rizzo, J
    Hammond, LA
    Takimoto, C
    Eckhardt, SG
    Tolcher, A
    Britten, CD
    Denis, L
    Ferrante, K
    Von Hoff, DD
    Silberman, S
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3267 - 3279
  • [37] Concurrent chemoradiation in unresectable extrahepatic biliary carcinoma. Long term results of a phase II study
    Manfrida, S
    Smaniotto, D
    Luzi, S
    Morganti, AG
    Trodella, L
    Deodato, F
    Costamagna, G
    Mantini, G
    Mutignani, M
    Macchia, G
    Cellini, N
    TUMORI, 2001, 87 (04) : S129 - S129
  • [38] A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma.
    Seki, S
    Yamada, T
    Kawakita, N
    Masuichi, H
    Kitada, T
    Sakaguchi, H
    HEPATOLOGY, 2000, 32 (04) : 617A - 617A
  • [39] Apoptotic effects of the docetaxel→OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells.
    Kimura, T
    Mahaffey, CM
    Pryde, BJ
    Mack, PC
    Davies, AM
    Gandara, DR
    Gumerlock, PH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 652S - 652S
  • [40] Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-α
    Yang, Jia-Lin
    Qu, Xian-Jun
    Hayes, Vanessa M.
    Brenner, Phillip C.
    Russell, Pamela J.
    Goldstein, David
    BJU INTERNATIONAL, 2007, 99 (06) : 1539 - 1545
12345